Publication details
Prognostic relevance of MYD88 mutations in CLL: the jury is still out
| Authors | |
|---|---|
| Year of publication | 2015 |
| Type | Article in Periodical |
| Magazine / Source | Blood |
| MU Faculty or unit | |
| Citation | |
| Web | http://www.bloodjournal.org/content/bloodjournal/126/8/1043.full.pdf |
| Doi | http://dx.doi.org/10.1182/blood-2015-05-648634 |
| Field | Oncology and hematology |
| Keywords | CHRONIC LYMPHOCYTIC-LEUKEMIA; GENES; SF3B1 |
| Attached files | |
| Description | Genome surveys have offered a comprehensive view of the genetic landscape of chronic lymphocytic leukemia (CLL), identifying several recurrently mutated genes, including myeloid differentiation primary response 88 (MYD88). The predominant mutation concerns a p.L265P substitution within exon 5,1,2 which leads to constitutive nuclear factor kappaB stimulation, thus conferring a proliferation and survival advantage to the mutant cells.1 MYD88 mutations reach up to 2% to 5% in CLL and are strikingly enriched among patients expressing mutated IGHV genes (M-CLL). |
| Related projects: |